NO20003967L - Farmasöytiske preparater - Google Patents

Farmasöytiske preparater

Info

Publication number
NO20003967L
NO20003967L NO20003967A NO20003967A NO20003967L NO 20003967 L NO20003967 L NO 20003967L NO 20003967 A NO20003967 A NO 20003967A NO 20003967 A NO20003967 A NO 20003967A NO 20003967 L NO20003967 L NO 20003967L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparations
preparations
pharmaceutical
Prior art date
Application number
NO20003967A
Other languages
English (en)
Other versions
NO312434B1 (no
NO20003967D0 (no
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003967(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO20003967D0 publication Critical patent/NO20003967D0/no
Publication of NO20003967L publication Critical patent/NO20003967L/no
Publication of NO312434B1 publication Critical patent/NO312434B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20003967A 2000-01-26 2000-08-04 Farmasöytiske preparater, samt anvendelse og fremgangsmåte for fremstilling derav NO312434B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
NO20003967D0 NO20003967D0 (no) 2000-08-04
NO20003967L true NO20003967L (no) 2001-07-27
NO312434B1 NO312434B1 (no) 2002-05-13

Family

ID=9884259

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20003968A NO327675B1 (no) 2000-01-26 2000-08-04 Farmasoytisk preparat inneholdende (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre eller et farmasoytisk akseptabelt salt derav.
NO20003967A NO312434B1 (no) 2000-01-26 2000-08-04 Farmasöytiske preparater, samt anvendelse og fremgangsmåte for fremstilling derav
NO20071303A NO327554B1 (no) 2000-01-26 2007-03-09 Farmasoytisk preparat inneholdende (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre eller et farmasoytisk akseptabelt salt derav.
NO2010005C NO2010005I1 (no) 2000-01-26 2010-03-10 (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,SS)-3,5-dihydroksyhept-6-ensyre eller et farmasøytisk akseptabeltsalt og et tribasisk fosfatsalt hvor kationet er flerverdig

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20003968A NO327675B1 (no) 2000-01-26 2000-08-04 Farmasoytisk preparat inneholdende (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre eller et farmasoytisk akseptabelt salt derav.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20071303A NO327554B1 (no) 2000-01-26 2007-03-09 Farmasoytisk preparat inneholdende (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre eller et farmasoytisk akseptabelt salt derav.
NO2010005C NO2010005I1 (no) 2000-01-26 2010-03-10 (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,SS)-3,5-dihydroksyhept-6-ensyre eller et farmasøytisk akseptabeltsalt og et tribasisk fosfatsalt hvor kationet er flerverdig

Country Status (48)

Country Link
US (2) US6548513B1 (no)
EP (6) EP1251831A1 (no)
JP (3) JP3267960B2 (no)
KR (3) KR100698333B1 (no)
CN (3) CN1149997C (no)
AP (2) AP1879A (no)
AR (3) AR025055A1 (no)
AT (3) ATE232088T1 (no)
AU (5) AU781269C (no)
BE (2) BE1013413A3 (no)
BG (4) BG65234B1 (no)
BR (2) BR0003365A (no)
CA (3) CA2315141C (no)
CH (2) CH691347A5 (no)
CL (1) CL2007001807A1 (no)
CR (3) CR6568A (no)
CZ (3) CZ298411B6 (no)
DE (3) DE10038108A1 (no)
DK (3) DK1223918T3 (no)
EE (3) EE05586B1 (no)
ES (2) ES2171123B1 (no)
FI (3) FI121365B (no)
FR (2) FR2804025B1 (no)
GB (3) GB0001621D0 (no)
HK (6) HK1036934A1 (no)
HR (3) HRP20020097B1 (no)
HU (2) HUP0003111A3 (no)
IL (4) IL147870A (no)
IS (3) IS1940B (no)
IT (2) ITTO20000779A1 (no)
ME (4) ME00191B (no)
MY (2) MY122707A (no)
NL (2) NL1015859C2 (no)
NO (4) NO327675B1 (no)
NZ (2) NZ531474A (no)
PL (2) PL341855A1 (no)
PT (3) PT102504A (no)
RS (1) RS50201B (no)
RU (2) RU2264210C2 (no)
SE (2) SE523481C2 (no)
SI (1) SI1223918T1 (no)
SK (2) SK283872B6 (no)
TR (3) TR200701171T2 (no)
TW (2) TW553749B (no)
UA (2) UA51853C2 (no)
WO (2) WO2001054668A1 (no)
YU (1) YU52902A (no)
ZA (2) ZA200003998B (no)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
ES2372682T5 (es) † 2000-04-10 2014-10-30 Teva Pharmaceutical Industries Ltd. Composiciones farmacéuticas estables que contienen ácidos 7-sustituidos-3,5-dihidroxiheptanoicos o ácidos 7-sustituidos-3,5-dihidroxiheptenoicos
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
WO2004016262A1 (ja) * 2002-08-12 2004-02-26 Kyowa Hakko Kogyo Co., Ltd. アミノ酸含有チュアブル錠
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
SI3395339T1 (sl) * 2003-09-12 2019-08-30 Amgen, Inc, Hitrotopna formulacija, ki vsebuje cinakalcet HCL
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
PT1689723E (pt) * 2003-12-02 2011-07-06 Teva Pharma Padrão referência para a caracterização de rosuvastatina
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
TW201240679A (en) * 2004-03-12 2012-10-16 Capsugel Belgium Nv Pharmaceutical formulations
EP2455067B1 (en) * 2004-05-04 2016-10-12 Innophos, Inc. Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
SG155189A1 (en) * 2004-08-06 2009-09-30 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
TWI345562B (en) * 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
JP2009515816A (ja) * 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
BRPI0605917A2 (pt) * 2005-08-16 2009-05-26 Teva Pharma intermediário cristalino de rosuvastatina
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
ES2375643T3 (es) * 2005-10-31 2012-03-02 Kowa Company, Ltd. Preparación farmacéutica que presenta excelente fotoestabilidad.
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
ES2564250T3 (es) * 2006-05-03 2016-03-21 Msn Laboratories Private Limited Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
WO2008044243A2 (en) * 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
AU2009208610A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of HMG CoA reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
WO2009150228A2 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
EP2309992B1 (en) * 2008-06-27 2017-10-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
WO2009156796A1 (en) * 2008-06-27 2009-12-30 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
WO2011018185A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
WO2012141160A1 (ja) * 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
JP6055465B2 (ja) 2011-05-20 2016-12-27 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ ロスバスタチンカルシウムの医薬組成物
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
PL2851075T3 (pl) * 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
US20160045497A1 (en) * 2013-03-12 2016-02-18 Lg Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
KR20170083071A (ko) 2014-11-11 2017-07-17 시오노기 앤드 컴파니, 리미티드 광에 대해서 불안정한 약물을 함유하는 다층 정제
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
EP3364946A4 (en) 2015-10-23 2019-06-26 Lyndra, Inc. STOMACH DISTRIBUTION SYSTEMS FOR DELAYED RELEASE OF THERAPEUTIC ACTIVE SUBSTANCES AND METHOD FOR THEIR USE
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
AU3214689A (en) * 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ES2064887T3 (es) 1990-09-13 1995-02-01 Akzo Nobel Nv Composiciones quimicas solidas estabilizadas.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
CA2150372C (en) 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
CZ288545B6 (cs) * 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
KR20010052557A (ko) 1998-06-05 2001-06-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 산화마그네슘을 사용한, ａｃｅ 억제제 함유 조성물의안정화
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001054688A1 (en) 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
CA2639407C (en) 2011-09-13
UA77156C2 (en) 2006-11-15
AP1449A (en) 2005-07-28
CA2639407A1 (en) 2001-07-26
ZA200003997B (en) 2000-08-14
BG106393A (en) 2002-07-31
JP2007182452A (ja) 2007-07-19
DE10038110B4 (de) 2006-06-29
NO327675B1 (no) 2009-09-07
IL150513A0 (en) 2003-02-12
ATE232088T1 (de) 2003-02-15
HK1036934A1 (en) 2002-01-25
HU0003110D0 (en) 2000-10-28
CN1282581A (zh) 2001-02-07
TWI228050B (en) 2005-02-21
CZ20002883A3 (cs) 2000-10-11
AP2002002591A0 (en) 2002-09-30
BR0003364A (pt) 2001-09-18
CZ299105B6 (cs) 2008-04-23
WO2001054669A1 (en) 2001-08-02
EE200200052A (et) 2003-04-15
KR100698333B1 (ko) 2007-03-23
TR200701171T2 (tr) 2007-04-24
AU2005202392C1 (en) 2016-06-02
HRP20080525A2 (en) 2008-12-31
AR025055A1 (es) 2002-11-06
RS50201B (sr) 2009-07-15
GB2358583B (en) 2002-02-06
AT412062B (de) 2004-09-27
DK178242B1 (da) 2015-09-28
KR100388713B1 (ko) 2003-06-25
SE0002826D0 (sv) 2000-08-04
IS1940B (is) 2004-07-16
DE10038110A1 (de) 2001-08-23
NO2010005I1 (no) 2010-05-03
SI1223918T1 (en) 2003-06-30
AU781269B2 (en) 2005-05-12
DE10038108A1 (de) 2001-08-02
HU222578B1 (hu) 2003-08-28
NO20003968L (no) 2001-07-27
MEP33808A (en) 2010-10-10
RU2206324C1 (ru) 2003-06-20
ITTO20000779A0 (it) 2000-08-04
NZ519774A (en) 2004-04-30
AP2002002409A0 (en) 2002-03-31
SE523471C2 (sv) 2004-04-20
SK283872B6 (sk) 2004-03-02
HK1040936A1 (en) 2002-06-28
GB0019029D0 (en) 2000-09-27
EE04990B1 (et) 2008-04-15
CH691347A5 (de) 2001-07-13
CN1319396A (zh) 2001-10-31
EE05221B1 (et) 2009-10-15
EP2133070A1 (en) 2009-12-16
HK1040936B (zh) 2010-06-11
HK1200368A1 (en) 2015-08-07
EP2774609A1 (en) 2014-09-10
FI20105657A (fi) 2010-06-10
FI20001749A0 (fi) 2000-08-04
PL196808B1 (pl) 2008-02-29
GB0001621D0 (en) 2000-03-15
RU2002122752A (ru) 2004-03-10
NL1015859A1 (nl) 2001-07-27
AU6580000A (en) 2001-08-07
CA2315141C (en) 2009-08-18
CR6687A (es) 2005-07-18
SE523481C2 (sv) 2004-04-20
SK11782000A3 (sk) 2001-12-03
ME00202B (me) 2010-10-10
FR2795324A1 (fr) 2000-12-29
FR2804025A1 (fr) 2001-07-27
ES2171123B1 (es) 2003-11-16
AU5184100A (en) 2001-08-02
SK11792000A3 (sk) 2001-12-03
FI20001750A (fi) 2001-07-27
BG106926A (bg) 2003-04-30
IL150513A (en) 2012-12-31
EP1251831A1 (en) 2002-10-30
HK1036935A1 (en) 2002-01-25
CR6568A (es) 2004-03-05
KR20000072135A (ko) 2000-12-05
DE60001371T2 (de) 2004-01-22
AP1879A (en) 2008-08-14
BG66168B1 (bg) 2011-10-31
YU5202A (sh) 2004-12-31
BG110353A (en) 2009-09-30
MY123650A (en) 2006-05-31
SE0002827L (sv) 2001-07-27
ZA200003998B (en) 2000-08-14
ITTO20000779A1 (it) 2002-02-04
GB0019028D0 (en) 2000-09-27
HUP0003110A3 (en) 2003-02-28
HUP0003111A2 (hu) 2002-02-28
JP2001206877A (ja) 2001-07-31
HRP20020632B1 (en) 2010-12-31
MEP33708A (en) 2010-10-10
HK1048950A1 (zh) 2003-04-25
BG66159B1 (bg) 2011-09-30
IL187416A0 (en) 2008-02-09
HUP0003111A3 (en) 2003-03-28
KR20010077840A (ko) 2001-08-20
CZ20002884A3 (cs) 2001-09-12
AR023624A1 (es) 2002-09-04
CL2007001807A1 (es) 2008-01-18
PT1223918E (pt) 2003-06-30
CN100528161C (zh) 2009-08-19
ITTO20000780A1 (it) 2000-11-04
BR0003365A (pt) 2001-09-18
EP2266540A1 (en) 2010-12-29
NO327554B1 (no) 2009-08-10
CH700184B1 (de) 2010-07-15
PT102503B (pt) 2004-02-27
EP1223918B1 (en) 2003-02-05
AU2000264559A1 (en) 2001-08-07
AT412063B (de) 2004-09-27
IL147870A0 (en) 2002-08-14
PT102504A (pt) 2001-07-31
SE0002827D0 (sv) 2000-08-04
ATA13612000A (de) 2004-02-15
JP2001206847A (ja) 2001-07-31
IS6254A (is) 2002-01-29
CN101028268A (zh) 2007-09-05
YU52902A (sh) 2006-01-16
JP4800467B2 (ja) 2011-10-26
ME00191B (me) 2010-10-10
AR060248A2 (es) 2008-06-04
TR200201888T2 (tr) 2002-11-21
NZ531474A (en) 2007-04-27
CN1149997C (zh) 2004-05-19
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
HK1047052A1 (zh) 2003-02-07
HUP0003110A2 (hu) 2001-05-28
PT102503A (pt) 2000-12-29
NO312434B1 (no) 2002-05-13
ES2171123A1 (es) 2002-08-16
AU2005202392B2 (en) 2008-11-20
AU2005202392A1 (en) 2005-06-30
ATA13602000A (de) 2004-02-15
HU0003111D0 (en) 2000-10-28
SE0002826L (sv) 2001-07-27
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
PL341853A1 (en) 2001-01-29
DK200001170A (da) 2001-01-27
KR20030036492A (ko) 2003-05-09
AU781269C (en) 2006-11-30
RU2264210C2 (ru) 2005-11-20
IS6480A (is) 2002-07-23
TR200200270T2 (tr) 2002-06-21
IS2805B (is) 2012-09-15
EE05586B1 (et) 2012-10-15
DK200001171A (da) 2001-07-27
WO2001054668A1 (en) 2001-08-02
BE1013413A3 (fr) 2001-12-04
DK1223918T3 (da) 2003-04-28
CZ298411B6 (cs) 2007-09-26
HRP20020097B1 (en) 2010-12-31
EE200900047A (et) 2011-04-15
NO20071303L (no) 2001-07-27
GB2358582B (en) 2004-09-29
CZ290167B6 (cs) 2002-06-12
IS8620A (is) 2007-03-07
EP1223918A1 (en) 2002-07-24
CA2313783A1 (en) 2000-10-16
FI111806B (fi) 2003-09-30
FR2795324B1 (fr) 2002-05-17
CR10114A (es) 2008-08-21
BG65234B1 (bg) 2007-09-28
JP3267960B2 (ja) 2002-03-25
BE1013414A5 (fr) 2001-12-04
MY122707A (en) 2006-04-29
EE200200411A (et) 2003-12-15
FI20001750A0 (fi) 2000-08-04
IL147870A (en) 2003-10-31
US6316460B1 (en) 2001-11-13
AU5184200A (en) 2001-08-02
AU738074B2 (en) 2001-09-06
PL341855A1 (en) 2001-07-30
FI121365B (fi) 2010-10-29
EP2018853A1 (en) 2009-01-28
FI20001749A (fi) 2001-07-27
JP4800988B2 (ja) 2011-10-26
NL1015859C2 (nl) 2001-10-16
NO20003967D0 (no) 2000-08-04
GB2358582A (en) 2001-08-01
HRP20020632A2 (en) 2004-12-31
UA51853C2 (uk) 2002-12-16
TW553749B (en) 2003-09-21
US6548513B1 (en) 2003-04-15
FR2804025B1 (fr) 2002-08-23
CA2313783C (en) 2002-03-12
DE60001371D1 (de) 2003-03-13
NL1015858C2 (nl) 2001-07-27
ES2155043B1 (es) 2001-12-01
CA2315141A1 (en) 2001-07-26
NO20003968D0 (no) 2000-08-04

Similar Documents

Publication Publication Date Title
NO20071303L (no) Farmasoytiske preparater
NO20033556D0 (no) Farmasöytiske preparater
ITTO20010008A0 (it) Formulazione farmaceutica
EE200200038A (et) Konservitud farmatseutilised preparaadid
IS6040A (is) Valdekoxib efnablöndur
DK1210113T3 (da) Kombinerede vaccinepræparater
DK1524266T3 (da) Farmaceutisk sammensætning
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
EE200300416A (et) Ravimvorm
DE50104433D1 (de) Desodorierende Zubereitungen
DE60126089D1 (de) Verabreichungssystem
DK1278416T3 (da) Flydende præparater
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
NO20022606D0 (no) Farmasöytiske kombinasjoner
NO20026123L (no) Farmasöytiske sammensetninger
IS6698A (is) Háhreinsaðar símvastatínblöndur
NO20031095D0 (no) Farmasöytiske sammensetninger
DE69926012D1 (de) Arzneizubereitungen
EE200100697A (et) Farmatseutiline kompleks
AR025867A1 (es) Formulacion portasdora farmaceutica
DE69906934D1 (de) Arzneizubereitungen
NO20032957L (no) Farmasöytisk emulsjonspreparat
DE50009295D1 (de) Vernetzerfreie zubereitungen

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: CRESTOR; NAT. REG. NO/DATE: MTNR 08-6072-75 20090914; FIRST REG. NO/DATE: RVG 26872 20021106

Spc suppl protection certif: 2010005

Filing date: 20100310

SPCX Expiry of an spc

Spc suppl protection certif: 2010005

MK1K Patent expired